UNSPSC 51111631: Dezaguanine

This classification denotes a purine antagonist with the molecular formula C6H6N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9DRB973HUI, chemically known as 6-aminoimidazo(4,5-c)pyridin-4(5h)-one but generally known as dezaguanine, which bears US NIH Compound Identifier 55710. European Medicines Agency schedules Dezaguanine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07057MIG.

UNSPSC 51111631 Dezaguanine is a Commodity code covering pharmaceutical active ingredients and precursor compounds used in drug manufacturing and compounding. State and local procurement under this code focuses on bulk pharmaceutical raw materials, chemical intermediates, and active pharmaceutical ingredients sourced for health department programs, corrections facilities, public health agencies, and state-administered pharmacy benefit initiatives. The recent activity shows state health and human services agencies soliciting information on direct-to-manufacturer pharmaceutical procurement models and supply chain arrangements that bypass traditional pharmacy benefit managers and wholesalers, indicating a shift toward value-based purchasing and negotiated net pricing for pharmaceutical inputs and finished medications.

The Texas Health and Human Services Commission issued a Request for Information (RFI) numbered HHS0017013 on April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI targeted vendors with experience in direct contracting for self-insured employers and government health plans, flexible negotiation capacity outside traditional GPO and PBM structures, and capability to support outcomes-based agreements. This represents exploratory procurement activity ahead of formal RFP issuance and reflects state-level interest in pharmaceutical supply-chain innovation, though no award value, budget ceiling, or formal evaluation timeline is specified in the current solicitation phase.